Status:
COMPLETED
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
OSI Pharmaceuticals
Conditions:
Non-Small Cell Lung Cancer
Phase:
PHASE3
Brief Summary
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study i...
Eligibility Criteria
Inclusion
- Exclusion Criteria:
Exclusion
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00085826
Start Date
April 1 2001
End Date
December 1 2004
Last Update
October 20 2011
Active Locations (114)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Hematology Oncology Associates
Birmingham, Alabama, United States, 35205
2
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, United States, 35235
3
Northern Arizona Hematology and Oncology Associates
Flagstaff, Arizona, United States, 86001
4
Hematology & Oncology Associates
Phoenix, Arizona, United States, 85012